Venus Remedies Ltd - 526953 - Audited Financial Results For The Quarter & Year Ended On 31.03.2019
Please find enclosed herewith Audited Financial Results for the quarter & year ended on 31.03.2019 along with Audit Report and statement of audit qualification which were taken on record by the Board of Directors at its meeting held on 30.05.2019. Venus Remedies Ltd - 526953 - Outcome of Board Meeting
This has reference to the meeting of Board of Directors dated 29th May, 2019, which was adjourned and continued on 30th May, 2019 i.e. today inter alia considered and approved as follows: 1. Audited Financial Results standalone and consolidated for the quarter and year ended on 31.03.2019 along with Audit Report. 2. Secretarial Audit Report as on 31.03.2019. 3. The resignation of Dr. Rupinder Tewari, Non-Executive and Independent Director taken on record. Meeting concluded at 9:40 pm. Venus Remedies Ltd - 526953 - Outcome of Board Meeting
With reference to the above, we hereby inform you that the meeting of Board of Directors of the Company held on Wednesday, 29th May 2019 is adjourned and will continue to be held on Thursday, 30th May 2019 to transact the agenda items. Further, the trading window would continue to remain closed till 48 hours from the publication of financial results for designated persons and their immediate relatives. VENUS REMEDIES LTD. - 526953 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report28/05/2019 3 Name of the Certifying Firm P. Chadha & Associates, Company Secretaries 4 Name of the Certifying Individual Prince Chadha 5Membership TypeACS 6 Membership Number 32856 7 CP No. 12409 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Resignation of Director
As per the Regulation 30 of SEBI (Listing obligation & Disclosure Requirements) Regulations 2015, we hereby inform that Dr. Rupinder Tewari, Non- Executive Independent Director of the Company has tendered his resignation from the Board of the Company w.e.f. 24th May 2019 due to professional occupancy. Further, as per the requirement of Regulation 30 read with Schedule III, Para A, Clause (7B) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith detailed reason for the resignation of Dr. Rupinder Tewari along with a confirmation that there is no other material reason other than mentioned by him for his resignation as the Independent Director from the Board of Directors of the Company. Venus Remedies Ltd - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pls find enclosed herewith newspaper publication for Notice of Board meeting to be held on 29.05.2019. VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Notice Of Board Meeting To Be Held On 29Th May 2019
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2019 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on Wednesday, 29th May 2019 to inter alia consider and approve Audited Financial Results for the quarter and year ended on 31st March 2019 and any other item with the permission of chair. Further, as informed vide letter dated 04.04.2019, the trading window would remain closed till 48 hours from the publication of financial results for designated persons and their immediate relatives. Venus Remedies Ltd - 526953 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996
In compliance with Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants)Regulation, 2018, we enclose herewith Confirmation Certificate received from our Registrar & Transfer Agent, M/s. Link Intime India Pvt Ltd. for the quarter ended 31.03.2019.. Venus Remedies Ltd - 526953 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayVENUS REMEDIES LTD. 2CININE411B01019 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY D 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Neha Designation: Company Secretary EmailId: complianceofficer@venusremedies.com Name of the Chief Financial Officer: Pawan Chaudhary Designation: CFO EmailId: complianceofficer@venusremedies.com Date: 24/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.